Comparison of estrogen and androgen levels after oral estrogen replacement therapy
- PMID: 11789085
Comparison of estrogen and androgen levels after oral estrogen replacement therapy
Abstract
Objective: To assess the extent of accumulation of circulating estrone (E1), total and free estradiol (E2) and estrone sulfate (E1S) levels in postmenopausal women receiving prolonged oral E2 therapy and to determine the effect of increased estrogenicity on free testosterone levels.
Study design: Descriptive study involving 14 healthy postmenopausal women during a three-year period. Group 1 (n = 7) took a placebo. Group 2 (n = 7) took 1 mg micronized E2 daily. Blood samples were taken at one, two and three years. E2, E1 and total testosterone were quantified by radioimmunoassay (RIA) following extraction and celite chromatography. Free testosterone and E2 were calculated. Sex hormone-binding globulin (SHBG) and E1S were quantified by RIA.
Results: In the control group, none of the hormone levels changed significantly. Free testosterone decreased 49% in women taking E2 replacement as compared to a 7% decline in women taking placebo. In women taking E2 replacement, E1, E2, E1S, free E2 and SHBG levels increased 10, 6, 51, 2 and 2 times, respectively, between baseline and year 3.
Conclusion: E1, E2 and E1S levels significantly increased with E2 replacement. Free testosterone levels decreased with E2 replacement. Testosterone replacement may be warranted when giving postmenopausal women estrogen replacement therapy.
Similar articles
-
Differences in the estrogen content of breast adipose tissue in women by menopausal status and hormone use.Obstet Gynecol. 1997 Aug;90(2):244-8. doi: 10.1016/S0029-7844(97)00212-3. Obstet Gynecol. 1997. PMID: 9241302
-
Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels--an association with mammographic density.Gynecol Endocrinol. 2005 Feb;20(2):110-5. doi: 10.1080/09513590400021151. Gynecol Endocrinol. 2005. PMID: 15823831 Clinical Trial.
-
The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.Menopause. 2008 Jan-Feb;15(1):94-7. doi: 10.1097/gme.0b013e318148b98b. Menopause. 2008. PMID: 17882008 Clinical Trial.
-
Testosterone deficiency in women.J Reprod Med. 2001 Mar;46(3 Suppl):291-6. J Reprod Med. 2001. PMID: 11304877 Review.
-
Pharmacokinetics of oral 17 beta-estradiol.J Reprod Med. 1992 Jan;37(1):77-84. J Reprod Med. 1992. PMID: 1548642 Review.
Cited by
-
Sex differences in β-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure.Brain Res. 2010 Dec 17;1366:233-45. doi: 10.1016/j.brainres.2010.10.009. Epub 2010 Oct 8. Brain Res. 2010. PMID: 20934413 Free PMC article.
-
Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort - a cross-sectional analysis.BMC Womens Health. 2008 Jan 14;8:1. doi: 10.1186/1472-6874-8-1. BMC Womens Health. 2008. PMID: 18194511 Free PMC article.
-
Menopausal hormone therapy and mortality among women diagnosed with ovarian cancer in the NIH-AARP Diet and Health Study.Gynecol Oncol Rep. 2015 May 8;13:13-7. doi: 10.1016/j.gore.2015.04.007. eCollection 2015 Aug. Gynecol Oncol Rep. 2015. PMID: 26425711 Free PMC article.
-
Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice.J Neurosci. 2007 Nov 28;27(48):13357-65. doi: 10.1523/JNEUROSCI.2718-07.2007. J Neurosci. 2007. PMID: 18045930 Free PMC article.
-
Circulating microparticles and endogenous estrogen in newly menopausal women.Climacteric. 2009 Apr;12(2):177-84. doi: 10.1080/13697130802488607. Climacteric. 2009. PMID: 19051075 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous